American Diabetes Association
DB21-0123-r2-Online_Appendix.pdf (1.97 MB)

Imeglimin Ameliorates β-cell Apoptosis by Modulating the Endoplasmic Reticulum Homeostasis Pathway

Download (1.97 MB)
posted on 2021-09-29, 15:40 authored by Jinghe Li, Ryota Inoue, Yu Togashi, Tomoko Okuyama, Aoi Satoh, Mayu Kyohara, Kuniyuki Nishiyama, Takahiro Tsuno, Daisuke Miyashita, Tatsuya Kin, A.M. James Shapiro, Resilind Su Ern Chew, Adrian Kee Keong Teo, Seiichi Oyadomari, Yasuo Terauchi, Jun Shirakawa
The effects of imeglimin, a novel anti-diabetes agent, on β-cell function remain unclear. Here, we unveiled the impact of imeglimin on β-cell survival. Treatment with imeglimin augmented mitochondrial function, enhanced insulin secretion, promoted β-cell proliferation, and improved β-cell survival in mouse islets. Imeglimin upregulated the expression of endoplasmic reticulum (ER)-related molecules including Chop (Ddit3), Gadd34 (Ppp1r15a), Atf3, and Sdf2l1, and decreased eIF2α phosphorylation, after treatment with thapsigargin, and restored global protein synthesis in β-cells under ER stress. Imeglimin failed to protect ER stress-induced β-cell apoptosis in CHOP-deficient islets or in the presence of GADD34 inhibitor. Treatment with imeglimin showed a significant decrease in the number of apoptotic β-cells and increased β-cell mass in Akita mice. Imeglimin also protected against β-cell apoptosis in both human islets and human pluripotent stem cell (hPSC)-derived β-like cells. Taken together, imeglimin modulates ER homeostasis pathway, which results in the prevention of β-cell apoptosis both in vitro and in vivo.


The authors acknowledge funding resources for this essential contribution to this work. This work was supported by a Grant-in-Aid for Young Scientists (B) 18K16240 from MEXT of Japan, a Junior Scientist Development Grant provided by Novo Nordisk Pharma Ltd., the Kanae Foundation for the Promotion of Medical Science, the Suzuken Memorial Foundation, the Japan Foundation for Applied Enzymology (FFDR), the Ono Medical Research Foundation, the Kamome Memorial Foundation of Yokohama City University, the Japan IDDM network, the Takeda Science Foundation, and the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to J.S.). A.K.K.T. and J.S. are supported by the AMED-A*STAR SCICOP Joint Call 192B9002. The authors have declared that no conflict of interest exists.


Usage metrics



    Ref. manager